Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Opthea ( (AU:OPT) ) has issued an announcement.
Opthea Limited announced the cessation of Julia Haller as a director of the company, effective June 2, 2025. This change in the board of directors could impact the company’s strategic direction and stakeholder interests, as Haller held significant unquoted options in the company, which could influence market perceptions and investor confidence.
The most recent analyst rating on (AU:OPT) stock is a Buy with a A$1.25 price target. To see the full list of analyst forecasts on Opthea stock, see the AU:OPT Stock Forecast page.
More about Opthea
Opthea Limited operates in the biotechnology industry, focusing on developing therapies for eye diseases. The company’s primary products are aimed at treating retinal diseases, with a significant emphasis on innovative treatments for conditions such as wet age-related macular degeneration.
YTD Price Performance: -25.93%
Average Trading Volume: 6,651,653
Technical Sentiment Signal: Sell
Current Market Cap: A$738.8M
For an in-depth examination of OPT stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue